PMV Pharmaceuticals, Inc. Company profile
About PMV Pharmaceuticals Inc
PMV Pharmaceuticals, Inc. is a precision oncology company. PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is focused on discovering and developing small molecule, tumor-agnostic therapies targeting p53 mutations. It’s lead product candidate, PC14586, is designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. The Company is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wild-type function. Its second program, R273H, targets the p53 R273H hotspot mutation.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, PMV Pharmaceuticals Inc revenues was not reported. Net loss increased 68% to $57.8M. Higher net loss reflects Research and development increase of 52% to $35.1M (expense), General and administrative increase of 81% to $17.9M (expense), Stock-based Compensation in SGA increase from $1.1M to $3.9M (expense).
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)